While there were no statistically significant differences between treatment groups in the intratumoural ratio of CD45− cells versus CD8+ T cells (which is roughly a measure of tumour burden divided by tumour-infiltrating cytotoxic T cells), the greatest reduction in the mean of this ratio was achieved by the triple combination therapy of PTX+B20+6E11 compared to controls (P < 0.05, Fig. 5d). The gene discussed is PTPRC; the disease is neoplasm.